A Phase 3 interventional study of fixed dose combination of telmisartan+amlodipine and amlodipine in Hypertension, sponsored by Boehringer Ingelheim. Completed at 129 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-27.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 22nd largest by enrollment of the 186 interventional ones that give a count, is one of 17 that started in 2007, is one of 69 in phase 3, and was the 52nd registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,098 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
122 studies in Hypertension by Boehringer Ingelheim: 1 open now, 1 under way, 1 of them phase 3. Of 120 finished, 41 (34%) have results posted.
Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 8th largest by enrollment of the 74 interventional ones that give a count, is one of 7 that started in 2007, is one of 43 in phase 3, and was the 31st registered.
Boehringer Ingelheim’s Hypertension studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
Among Boehringer Ingelheim’s 122 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this trial are (a) to demonstrate that the fixed-dose combination T40/A5 or the fixed-dose combination T80/A5 is superior in reducing blood pressure at eight weeks compared with A5 (b) to demonstrate that the fixed-dose combination T40/A5 or the fixed-dose combination T80/A5 is not inferior in reducing blood pressure at eight weeks compared with A10 and (c) to demonstrate that the incidence of oedema on the fixed-dose combination T40/A5 pooled with the fixed-dose combination T80/A5 is superior (less oedema) to A10 in patients who fail to respond adequately to six weeks treatment with A5.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP)
Change from baseline to the end of study in trough DBP
Time frame: End of study (8 weeks or last value on treatment)
Number of Patients With Oedema
Patients from the treated set who experienced at least one case of general oedema.
Time frame: During randomised treatment period (8 weeks was the planned end of treatment, some of the measurements analysed as end of study can be at 4 weeks or at any point on randomised treatment)
Change From Baseline in Trough Seated Systolic Blood Pressure (SBP)
Change from baseline to the end of study in trough SBP
Time frame: End of study (8 weeks or last value on treatment)
Trough Seated Diastolic Blood Pressure Control
The number of patients who reach the target DBP of \<90mmHg
Time frame: End of study (8 weeks or last value on treatment)
Trough Seated DBP Response
The number of patients who reach the target DBP of \<90mmHg or had a reduction in DBP \>= 10mmHg
Time frame: End of study (8 weeks or last value on treatment)
Trough Seated SBP Control
The number of patients who reach the target SBP of \<140mmHg
Time frame: End of study (8 weeks or last value on treatment)
Trough Seated SBP Response
The number of patients who reach the target SBP of \<140mmHg or had a reduction in SBP \>= 15 mmHg
Time frame: End of study (8 weeks or last value on treatment)
Trough Seated Blood Pressure (BP) Normality Classes
The number of patients who reach predefined BP categories: * Optimal - SBP\<120 and DBP\<80 mmHg * Normal - SBP\<130 and DBP\<85 mmHg * High-normal - SBP\<140 DBP\<90 mmHg * Stage 1 hypertension - SBP\<160 and DBP\<100 * Stage 2 hypertension SBP\>=160 and DBP\>=100 mmHg
Time frame: End of study (8 weeks or last value on treatment)
| Milestone | Amlodipine 5mg | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg |
|---|---|---|---|---|
| Started | 267 | 276 | 277 | 277 |
| Completed | 255 | 252 | 273 | 266 |
| Not completed | 12 | 24 | 4 | 11 |
| Withdrew: Adverse event | 6 | 22 | 3 | 4 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 2 |
| Withdrew: Non compliant with protocol | 1 | 0 | 0 | 3 |
| Withdrew: Consent withdrawn | 2 | 1 | 0 | 1 |
| Withdrew: Other | 3 | 0 | 0 | 1 |
Change from baseline to the end of study in trough DBP
| mmHg | Amlodipine 5mg | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg |
|---|---|---|---|---|
| Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) | -5.71 ± 0.49 | -7.95 ± 0.49 | -9.35 ± 0.48 | -10.63 ± 0.48 |
Change from baseline to the end of study in trough SBP
| mmHg | Amlodipine 5mg | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg |
|---|---|---|---|---|
| Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) | -6.18 ± 0.73 | -11.11 ± 0.72 | -13.56 ± 0.71 | -14.99 ± 0.71 |
The number of patients who reach the target DBP of \<90mmHg
| patients | Amlodipine 5mg | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg |
|---|---|---|---|---|
| Yes (DBP<90 mmHg) | 107 | 148 | 153 | 173 |
| No (DBP>=90 mmHg) | 148 | 113 | 117 | 98 |
The number of patients who reach the target DBP of \<90mmHg or had a reduction in DBP \>= 10mmHg
| patients | Amlodipine 5mg | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg |
|---|---|---|---|---|
| Yes (Responder) | 116 | 163 | 177 | 187 |
| No (Non-responder) | 139 | 98 | 93 | 84 |
The number of patients who reach the target SBP of \<140mmHg
| patients | Amlodipine 5mg | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg |
|---|---|---|---|---|
| Yes (SBP<140 mmHg) | 100 | 142 | 162 | 178 |
| No (SBP>=140 mmHg) | 155 | 119 | 108 | 93 |
The number of patients who reach the target SBP of \<140mmHg or had a reduction in SBP \>= 15 mmHg
| patients | Amlodipine 5mg | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg |
|---|---|---|---|---|
| Yes (Responder) | 118 | 166 | 187 | 200 |
| No (Non-responder) | 137 | 95 | 83 | 71 |
The number of patients who reach predefined BP categories: * Optimal - SBP\<120 and DBP\<80 mmHg * Normal - SBP\<130 and DBP\<85 mmHg * High-normal - SBP\<140 DBP\<90 mmHg * Stage 1 hypertension - SBP\<160 and DBP\<100 * Stage 2 hypertension SBP\>=160 and DBP\>=100 mmHg
| patients | Amlodipine 5mg | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg |
|---|---|---|---|---|
| Optimal | 2 | 5 | 19 | 21 |
| Normal | 23 | 30 | 35 | 51 |
| High-normal | 42 | 68 | 63 | 67 |
| Stage 1 hypertension | 118 | 126 | 127 | 110 |
| Stage 2 hypertension | 70 | 32 | 26 | 22 |
Patients from the treated set who experienced at least one case of general oedema.
| patients | Amlodipine 5mg | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg |
|---|---|---|---|---|
| Number of patients with any oedema | 23 | 76 | 14 | 10 |
| Number of patients with general oedema | 23 | 75 | 14 | 10 |
Collected over From day of first dose until one day after last dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Amlodipine 5mg | — | 2/267 (0.7%) | 22/267 (8.2%) |
| Amlodipine 10mg | — | 1/276 (0.4%) | 74/276 (26.8%) |
| Telmisartan 40mg and Amlodipine 5mg | — | 2/277 (0.7%) | 14/277 (5.1%) |
| Telmisartan 80mg and Amlodipine 5mg | — | 1/277 (0.4%) | 10/277 (3.6%) |
| Event | Amlodipine 5mg | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg |
|---|---|---|---|---|
| Atrial fibrilationCardiac disorders | 1/267 | 0/276 | 0/277 | 0/277 |
| Chest painGeneral disorders | 1/267 | 0/276 | 0/277 | 0/277 |
| Breast massReproductive system and breast disorders | 0/267 | 1/276 | 0/277 | 0/277 |
| Chest discomfortGeneral disorders | 0/267 | 0/276 | 0/277 | 1/277 |
| PneumoniaInfections and infestations | 0/267 | 0/276 | 1/277 | 0/277 |
| Bronchial carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/267 | 0/276 | 1/277 | 0/277 |
| Event | Amlodipine 5mg | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg |
|---|---|---|---|---|
| Oedema peripheralGeneral disorders | 22/267 | 74/276 | 14/277 | 10/277 |
| Age, Continuous(Years) | Amlodipine 5mg | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg | Total |
|---|---|---|---|---|---|
| Mean | 54 ± 10.6 | 54.3 ± 10.6 | 53.9 ± 11 | 54.5 ± 10.2 | 54.2 ± 10.6 |
| Sex: Female, Male(Participants) | Amlodipine 5mg | Amlodipine 10mg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg | Total |
|---|---|---|---|---|---|
| Female | 104 | 100 | 117 | 94 | 415 |
| Male | 163 | 176 | 160 | 183 | 682 |
Showing the first 100 of 129 sites across 12 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2007 and a primary completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlodipine